TG Therapeutics, Inc. (LON:0VGI)
30.39
-6.72 (-18.11%)
Jan 9, 2026, 3:11 PM GMT
TG Therapeutics Revenue
TG Therapeutics had revenue of $161.71M USD in the quarter ending September 30, 2025, with 92.79% growth. This brings the company's revenue in the last twelve months to $531.90M, up 100.88% year-over-year. In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth.
Revenue (ttm)
$531.90M
Revenue Growth
+100.88%
P/S Ratio
7.80
Revenue / Employee
$1.42M
Employees
374
Market Cap
3.09B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
| Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
| Dec 31, 2020 | 152.00K | - | - |
| Dec 31, 2019 | 152.00K | - | - |
| Dec 31, 2018 | 152.00K | - | - |
| Dec 31, 2017 | 152.00K | - | - |
| Dec 31, 2016 | 152.00K | -381.00 | -0.25% |
| Dec 31, 2015 | 152.38K | - | - |
| Dec 31, 2014 | 152.38K | - | - |
| Dec 31, 2013 | 152.38K | 133.33K | 699.98% |
| Dec 31, 2012 | 19.05K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| CVS Group | 673.20M |
| Genus | 672.80M |
TG Therapeutics News
- 4 days ago - TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis - GlobeNewsWire
- 6 days ago - TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - GlobeNewsWire
- 9 days ago - Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares - The Motley Fool
- 10 days ago - JP Morgan Adjusts Price Target for TGTX, Maintains Overweight Rating | TGTX Stock News - GuruFocus
- 23 days ago - TOTH FINANCIAL ADVISORY CORP Sells 100 Shares of TG Therapeutics Inc (TGTX) - GuruFocus
- 4 weeks ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch
- 4 weeks ago - TG Therapeutics: The "Exit Velocity" You Can't Ignore (Rating Upgrade) - Seeking Alpha
- 4 weeks ago - Goldman Sachs Raises Price Target for TG Therapeutics (TGTX) to $39 | TGTX Stock News - GuruFocus